Thromboembolic risk and depot medroxyprogesterone

Depot medroxyprogesterone is not associated with a clinically significant risk of VTE. Despite a small increase in VTE risk if started in the first week postpartum, it is considered safe to use (UKMEC 2) immediately postpartum.